Consider the Goldilocks approach to psychedelics
Researchers have long established that mind-bending doses of psychedelic drugs can have antidepressive benefits. And enthusiasts have long claimed (with debatable evidence) that microdosing psilocybin makes them better at their jobs. But what about the middle way?
Shlomi Raz is the CEO of the London-based Eleusis, which is among the companies, nonprofits, and government departments researching whether it’s possible to get all the benefits of high-dose psychedelic treatment without the associated trip.
This kind of work is not yet the stuff of multinational pharmaceutical investment, but Raz, writing in STAT, thinks that will change. As more evidence points to the efficacy of low-dose psychedelics and the possibility of engineering molecules that convey the physical benefits without the psychoactive risks, formerly outré research should enter the mainstream, according to Raz.
Read more.
Shlomi Raz is the CEO of the London-based Eleusis, which is among the companies, nonprofits, and government departments researching whether it’s possible to get all the benefits of high-dose psychedelic treatment without the associated trip.
This kind of work is not yet the stuff of multinational pharmaceutical investment, but Raz, writing in STAT, thinks that will change. As more evidence points to the efficacy of low-dose psychedelics and the possibility of engineering molecules that convey the physical benefits without the psychoactive risks, formerly outré research should enter the mainstream, according to Raz.
Read more.
.png)
No hay comentarios:
Publicar un comentario